Stay updated with breaking news from Expanded Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Webinar to take place on Monday, June 5, 2023 at 12:30 PM ETNEW YORK, May 25, 2023) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes
Highlights Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy...
Highlights Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy with 67Cu SAR-bisPSMA at the lowest dose level of 4GBq. No dose limiting toxicities (DLTs) have been reported in cohort 1. The Safety Review Committee (SRC) has recommended that the trial continues to cohort 2. Recruitment has opened at clinical sites in the United States (US) at the cohort 2 dose level of 8GBq and patients are currently in screening for all available slots. Additional therapy cycles of 67Cu SAR-bisPSMA have been requested...
Highlights SYDNEY, May 24, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the completion of cohort 1 and advancement to cohort 2 in the therapeutic phase of its Phase I/II...
RedHill has elected to terminate RHB-204's U.S. Phase 3 study for Non-tuberculosis Mycobacteria disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107... | May 22, 2023